26 July 2018 
EMA/CHMP/491031/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Slenyto 
melatonin 
On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Slenyto, 
intended for the treatment of insomnia in children and adolescents with autism spectrum disorder (ASD) 
or Smith-Magenis syndrome. The applicant for this medicinal product is RAD Neurim Pharmaceuticals EEC 
Ltd. 
Slenyto will be available as 1-mg and 5-mg prolonged-release tablets. The active substance of Slenyto is 
melatonin (ATC code: N05CH01), which promotes sleep by activation of melatonin receptors.  
The benefits with Slenyto are its ability to increase sleep duration. The most common side effects are 
somnolence, fatigue and mood swings.  
The full indication is: “Slenyto is indicated for the treatment of insomnia in children and adolescents aged 
2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene 
measures have been insufficient.” 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
